<DOC>
	<DOCNO>NCT00004051</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase I trial study effectiveness irinotecan treating patient advance solid tumor .</brief_summary>
	<brief_title>Irinotecan Treating Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose , dose limit toxicity , safety profile oral irinotecan patient advance solid tumor . II . Characterize single multiple dose pharmacokinetics oral irinotecan metabolite , SN-38 SN-38 glucuronide , patient . III . Document antitumor activity patient treat regimen . OUTLINE : This dose escalation study . Patients receive oral irinotecan daily 14 day . Courses repeat every 3 week absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos irinotecan maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose limit toxicity . Patients follow monthly 6 month . PROJECTED ACCRUAL : Approximately 3-40 patient accrue study .</detailed_description>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven advanced solid tumor curative therapy exist No leukemias lymphoma Brain leptomeningeal disease allow prior irradiation lesion , concurrent corticosteroid , clinical symptom PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : At least 12 week Hematopoietic : Absolute neutrophil count least 2,000/mm3 Platelet count least 150,000/mm3 Hemoglobin least 9.0 g/dL Hepatic : Bilirubin great 1.5 mg/dL regardless liver tumor presence SGOT great 3 time upper limit normal ( ULN ) ( 5 time ULN due liver tumor ) Renal : Creatinine great 2.0 mg/dL Cardiovascular : No uncontrolled high blood pressure No unstable angina No symptomatic congestive heart failure No myocardial infarction within past 6 month No serious uncontrolled cardiac arrhythmia Gastrointestinal : No active inflammatory bowel disease No significant bowel obstruction No chronic malabsorption Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No active infection HIV negative No AIDS relate illness No significant alcoholism substance abuse No severe medical psychiatric illness would preclude participation study PRIOR CONCURRENT THERAPY : At least 4 week since prior therapy cancer recover Biologic therapy : No concurrent immunotherapy No concurrent filgrastim ( GCSF ) , sargramostim ( GMCSF ) , epoetin alfa Chemotherapy : No prior nitrosoureas , mitomycin , irinotecan No prior high dose chemotherapy support peripheral blood stem cell transplantation No concurrent chemotherapy Endocrine therapy : No concurrent hormonal therapy Radiotherapy : No prior irradiation pelvis No concurrent radiotherapy Surgery : No prior gastrectomy total colectomy Other : At least 1 week since prior anticonvulsant No concurrent investigational drug No combination anticholinergic medication contain barbiturate ( e.g. , Donnatol )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>